Liquidia Corporation
LQDA$686M
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaMORRISVILLE170 employees
Drugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Jun 27, 2026
19wData is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply
Market Overview
Stock performance and market intelligence
Catalyst Timeline
1 upcoming, 0 past
🎯PDUFANext
FDA PDUFA Date LIQ861 (standard)
6/27/2026
For pulmonary arterial hypertension. NDA filing. Extracted from SEC filing: 8-K
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Drug Pipeline
LIQ861 Inhaled Treprostinil
Primary Pulmonary Hypertension
Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
Influenza
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
LIQ861 Inhaled Treprostinil | Phase 3 | Primary Pulmonary Hypertension | - |
Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) | Phase 2 | Influenza | - |
Regulatory & News
Approvals, filings, and latest developments
Regulatory Approvals
LQDA News